B-PEA-MBSA + H-HPA-NSA

B-PEA-MBSA + H-HPA-NSA is an experimental combination of two sulfonic acid functionalized small molecules designed to inhibit β-amyloid (Aβ) aggregation, a key pathological process in Alzheimer's disease. Both compounds have demonstrated the ability to prevent Aβ aggregation in vitro and reduce oxidative stress in neuronal cell models. In kinetic studies, H-HPA-NSA was shown to arrest the elongation phase of Aβ aggregation at low concentrations (10 μM), while B-PEA-MBSA reduced the intensity of the stationary phase at higher concentrations (100 μM). The combination is being investigated for its potential as a disease-modifying therapy for mild to moderate Alzheimer's disease by targeting amyloid plaque formation and associated neurotoxicity[1][2].